Ahn Y - Search Results

1

Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).

Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Rhee MY, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HS. Kim KJ, et al. Among authors: ahn y. Cardiovasc Ther. 2016 Oct;34(5):371-82. doi: 10.1111/1755-5922.12213. Cardiovasc Ther. 2016. PMID: 27506635 Free PMC article. Clinical Trial.

2

Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.

Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC. Hong YJ, et al. Among authors: ahn y. Circ J. 2005 Dec;69(12):1477-83. doi: 10.1253/circj.69.1477. Circ J. 2005. PMID: 16308495 Free article.

3

Preinterventional peak monocyte count and in-stent intimal hyperplasia after coronary stent implantation in human coronary arteries.

Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC. Hong YJ, et al. Among authors: ahn y. Clin Cardiol. 2005 Nov;28(11):512-8. doi: 10.1002/clc.4960281105. Clin Cardiol. 2005. PMID: 16450794 Free PMC article.

4

Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting.

Hong YJ, Jeong MH, Lim SY, Lee SR, Hong SN, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC. Hong YJ, et al. Among authors: ahn y. Am J Cardiol. 2006 Aug 1;98(3):341-5. doi: 10.1016/j.amjcard.2006.02.037. Epub 2006 Jun 12. Am J Cardiol. 2006. PMID: 16860020

5

The effects of granulocyte-colony stimulating factor in bare stent and sirolimus-eluting stent in pigs following myocardial infarction.

Lim SY, Kim YS, Ahn Y, Jeong MH, Rok LS, Kim JH, Kim KH, Park HW, Kim W, Cho JG, Park JC, Kang PM, Schwartz RS, Kang JC. Lim SY, et al. Among authors: ahn y. Int J Cardiol. 2007 Jun 12;118(3):304-11. doi: 10.1016/j.ijcard.2006.07.018. Epub 2006 Oct 17. Int J Cardiol. 2007. PMID: 17052793

6

Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.

Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. Kim YS, et al. Among authors: ahn y. J Cardiovasc Pharmacol. 2007 Jun;49(6):376-83. doi: 10.1097/FJC.0b013e31804a5e34. J Cardiovasc Pharmacol. 2007. PMID: 17577102

7

Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells.

Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. Kim YS, et al. Among authors: ahn y. J Cardiovasc Pharmacol. 2007 Jul;50(1):41-9. doi: 10.1097/FJC.0b013e31805559b9. J Cardiovasc Pharmacol. 2007. PMID: 17666914

8

Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.

Kim SH, Kim YD, Lim DS, Yoon MH, Ahn YK, On YK, Lee JW, Kim IJ, Park JB, Kim JJ, Chung WS, Yang JY, Seo HS, Shin EK, Kim HS; Korean Multicenter Amlodipine Study Investigators. Kim SH, et al. Clin Ther. 2007 Sep;29(9):1924-36. doi: 10.1016/j.clinthera.2007.09.018. Clin Ther. 2007. PMID: 18035192 Clinical Trial.

9

Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.

Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK. Ahn Y, et al. Among authors: ahn th. Circ J. 2008 Jan;72(1):35-9. doi: 10.1253/circj.72.35. Circ J. 2008. PMID: 18159096 Free article. Clinical Trial.

10

A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention.

Moon JY, Kim W, Kim JH, Ahn Y, Jeong MH, Kim YH, Hong MK, Park SW, Park SJ, Park S, Ko YG, Choi D, Jang Y. Moon JY, et al. Among authors: ahn y. Yonsei Med J. 2008 Jun 30;49(3):389-99. doi: 10.3349/ymj.2008.49.3.389. Yonsei Med J. 2008. PMID: 18581587 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,503 results

Search Page

Filters